These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33545570)

  • 21. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
    Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
    Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
    Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
    Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.
    Nik ME; Jaafari MR; Mashreghi M; Nikoofal-Sahlabadi S; Amin M; Sadeghnia HR; Iranshahi M; Navashenaq JG; Malaekeh-Nikouei B
    Int J Pharm; 2021 Jul; 604():120710. PubMed ID: 34019972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
    Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
    J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
    Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
    PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
    Herringson TP; Altin JG
    J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice.
    Mehrabian A; Dadpour S; Mashreghi M; Zarqi J; Askarizadeh A; Badiee A; Arabi L; Moosavian SA; Jaafari MR
    IET Nanobiotechnol; 2023 Apr; 17(2):112-124. PubMed ID: 36594666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
    Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
    J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
    Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
    Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.
    Soleimani A; Mirzavi F; Nikoofal-Sahlabadi S; Nikpoor AR; Taghizadeh B; Barati M; Soukhtanloo M; Jaafari MR
    Sci Rep; 2022 Jun; 12(1):10423. PubMed ID: 35729230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma.
    Rastgoo M; Hosseinzadeh H; Alavizadeh H; Abbasi A; Ayati Z; Jaafari MR
    Planta Med; 2013 Apr; 79(6):447-51. PubMed ID: 23539350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.
    Kousani S; Karimi M; Teymouri M; Navashenaq JG; Darban SA; Jaafari MR
    Biotechnol Prog; 2021 Nov; 37(6):e3202. PubMed ID: 34405574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.